Summary
HAE Chart
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.
Why Haemonetics (HAE) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Pharvaris: Biotech With De-Risked Phase 3 Readout Coming, Initiating With A Buy Rating
I initiate Pharvaris with a buy rating and $40 target price, driven by its differentiated oral bradykinin B2 antagonist franchise for HAE. PHVS's late-stage pipeline targets both on-demand and prophylactic HAE treatment, with pivotal phase 3 data expected by year-end 2025. Deucrictibant's validated mechanism, strong phase 2 results, and regulatory precedent de-risk the upcoming phase 3 readout, supporting a high probability of success of 90%+ (author's judgement).
Haemonetics Corporation (HAE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Haemonetics Corporation ever had a stock split?
Haemonetics Corporation Profile
| - Industry | - Sector | Christopher A. Simon CEO | NYSE Exchange | 405024100 CUSIP |
| US Country | 3,657 Employees | - Last Dividend | 3 Dec 2012 Last Split | 9 May 1991 IPO Date |
Overview
Haemonetics Corporation is a leading healthcare provider that specializes in developing a comprehensive suite of medical products and solutions. With a global presence, the company is dedicated to enhancing the efficiency and safety of blood and plasma collection, processing, and management. Founded in 1971 and headquartered in Boston, Massachusetts, Haemonetics Corporation has been at the forefront of innovation, offering advanced technologies to support hospitals, blood banks, and plasma collection centers in improving patient care and outcomes.
Products and Services
- Automated Plasma Collection Systems and Software Solutions:
Includes NexSys PCS and PCS2 plasmapheresis equipment, related disposables, and intravenous solutions. Offers integrated IT platforms like NexLynk DMS donor management system and Donor360, designed for plasma customers to streamline donor management, operations, and supply chain management.
- Automated Blood Component and Manual Whole Blood Collection Systems:
Features the MCS brand apheresis equipment, which enables the collection of specific blood components from donors. Also provides disposable collection and component storage sets, SafeTrace Tx blood bank information system, and BloodTrack management software, facilitating efficient blood management and transfusion processes.
- Hospital Products:
Offers TEG, ClotPro, and HAS hemostasis analyzer systems for a comprehensive assessment of a patient's hemostasis. TEG Manager software connects TEG analyzers across the hospital, allowing clinicians remote access to test results to inform treatment decisions. Cell Saver Elite +, an autologous blood recovery system, is suited for various surgeries, enhancing recovery and minimizing transfusion needs.
- VASCADE Products:
Including VASCADE and VASCADE MVP, this technology platform leverages the natural clotting mechanism with a catheter-based delivery system for vascular closure, designed to improve patient outcomes and reduce recovery time after procedures.
Contact Information
